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Abstract
Adolescents and young adults (AYA) surviving classical Hodgkin lymphoma (cHL) risk long term
fatal treatment-related toxicities. We utilized the Surveillance, Epidemiology and End Results
(SEER) program to compare excess mortality rate (EMR-observed minus expected mortality) for
10-year survivors of AYA cHL diagnosed in 1973–1992 and 1993–2003 eras. The 15-year EMR
reduced from 4.88% to 2.19% while the 20-year EMR reduced from 9.46% to 4.07% between
eras. Survivors of stages 1–2 had lower EMR than survivors of stages 3–4 cHL in the 1993-2003
but not in the 1973–1992 era. There was an overall decline in risk of death between 10 and 15
years from diagnosis, driven mostly by second neoplasms and cardiovascular mortality. Despite
reduction in fatal second neoplasms and cardiovascular disease with more current therapy, long
term survivors of AYA cHL still have a higher risk of death than the general population highlighting
the need for safer therapies.
1 | INTRODUCTION
Adolescents and young adults (AYA) constitute the majority of patients
with classical Hodgkin lymphoma (cHL), and most of those patients will
be cured with multi-agent chemotherapy or combined used of chemo-
therapy and radiation therapy.1 However, this therapeutic success has
been hindered by the development of significant treatment-related late
toxicities.2,3 In addition to having a high risk of developing second
malignant neoplasms (SMN), cHL survivors face a variety of chronic
medical conditions linked to cancer therapy.4 Treatment-induced
chronic illness and SMN contribute to premature deaths among cHL
survivors.5
Successive generations of cHL therapy over the past several deca-
des have modified the long term risk and toxicity profile of survivors.
The early 1990s marks the transition between use of higher dose,
extended-field radiation, and MOPP (mechlorethamine, vincristine,
procarbazine, and prednisone) chemotherapy6 to lower doses,
involved-field radiation, and ABVD (adriamycin, bleomycin, vinblastine,
and dacarbazine) regimen as more common approaches to treat
patients with cHL.7 More recently, both pediatric and adult studies
have focused on early risk stratification and response-adapted therapy
to tailor treatment strategies.8
Those approaches have led to further improvement in survival rates
and risk reduction of therapy related long-term toxicities as exemplified in
a large cohort of pediatric cHL survivors.9 The increased risk of death in
long-term survivors and the temporal trends in such risk have not been
well characterized at the population level, particularly in young adults. In
this study, we utilized a large population-based data set focusing on AYA
cHL survivors to better understand and compare excess mortality in 2
consecutive eras. We aimed to evaluate possible factors associated with
late excess mortality, and described and compared causes of death among
10-year survivors of AYA cHL across different time periods.
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2 | METHODS
Using data from the National Cancer Institute (NCI) Surveillance Epide-
miology and End Results (SEER) program, we analyzed the excess mor-
tality rate (EMR) of 10-year cHL AYA survivors treated in 2 distinct
eras based on the year of diagnosis, 1973–1992 and 1993–2003,
reflecting the development of risk-adapted response-based treatment
approach and treatment de-intensification.6 For cHL, SEER collects
data, when available, on histological subtype, Ann-Arbor staging (avail-
able since 1983) and the use of radiation therapy, but not on the use
of systemic therapy or hematopoietic cell transplantation. Additionally,
SEER collects survival status, occurrence of subsequent malignancies
and cause of death.
Participating registries in SEER-18 comprise the Alaska Native,
Atlanta, Connecticut, Detroit, Greater California, Greater Georgia,
Hawaii, Iowa, Kentucky, Los Angeles, Louisiana, New Jersey, New
Mexico, San Francisco-Oakland, San Jose-Monterey, Rural Georgia,
Seattle-Puget Sound, and the Utah Tumor Registry, corresponding to
approximately 28% of the US population (based on the 2000 census).
We included all patients between the ages of 15–39 years at the time
of cHL diagnosis. We identified cHL cases using the third edition of the
International Classification of Disease for Oncology (ICD-O-3) histology
codes 9650/3–9655/3, and 9661/3–9667/3 (cHL) diagnosed between
1973–1992 or 1993–2003 as a first malignant neoplasm. The age
range was chosen to match the NCI definition of “adolescent and
young adult”. Only patients known to be alive at 10 years from diagno-
sis were included in the analysis. Follow-up was updated to the end of
2013 (November 2015 submission), so patients in the most recent
cohort had at least 10 years of follow-up.
2.1 | Data analysis and statistics
We described the population included utilizing the case listing session
function of SEER*Stat Version 8.3.2. We obtained actual and expected
survival at time points of interest utilizing the survival function in
SEER*Stat using the US census of 2000 as reference. Since the study
addresses exclusively 10-year survivors, actual and expected mortality
were adjusted to 0% at 10 years for the cohorts being studied. The
main parameter studied was EMR, which is, the difference between
the observed mortality rate in the cohort being studied and the
expected mortality rate in a contemporaneous population of similar
age, gender, and race/ethnicity structure. Along with relative survival,
EMR is a possible approach to compare observed and expected survival
(or mortality) of a cohort. EMR is defined as “the death rate in the gen-
eral population due to the excess risk imposed by specific disease”.10
We chose to use EMR as it provides a more direct and intuitive way to
measure the impact of the condition being studied (in this case being a
10-year survivor of AYA cHL) on the risk of death. For example, an
EMR of 5% detected between years 10 and 15 from diagnosis mean
that patients who are 10-year cHL survivors have a 5% higher absolute
risk of dying during the 5 subsequent years than individuals of similar
age, gender, and race/ethnicity in the population who are not cHL
survivors.
We compared EMR in 10-year cHL survivors diagnosed between
time periods of 1973–1992 and 1993–2003. We subsequently
explored the impact of gender, stage, and use of radiation treatment (for
patients with localized stage) on EMR across the 2 eras. We intended to
compare cause of death (COD) among the 10-year AYA cHL survivors
between the 2 eras. However, the 2 cohorts inherently have a different
duration of follow-up and contain survivors who reach very distinct
ages. For instance, a 25 year-old patient diagnosed at the onset of the
1973–1992 era would have a follow-up until the age of 65, while a
25-year-old patient diagnosed at the onset of the 1993–2003 era would
have a follow-up until the age of 45, encompassing periods of life where
risk of death in the population is very dissimilar. We corrected this dis-
crepancy by analyzing COD in a short time-period of 5 years (beginning
10 to 15 years from diagnosis) in the subsets of cohorts with at least 15
years of follow-up. Therefore, in this study, COD is described and com-
pared for patients diagnosed in two 5-year time-periods, 1983–1987
and 1993–1997, respectively. Of note, 1983–1987 was chosen as the
first time-period given the fact that staging for cHL was only reported
in SEER on and after 1983. The cause-specific risk of death during the
5-year period is described in deaths/1000 person-year at risk.
Comparisons between rates were performed using Z-test. We
performed statistical analysis using SPSS (IBM Corp. Released 2013.
IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY). Statistical
tests were 2-sided and considered significant when P< .05.
3 | RESULTS
3.1 | Population
Table 1 delineates the characteristics of the patients diagnosed during
the time periods of 1973–1992 (N56480) and 1993–2003
(N55870). Median follow-up was 312 months (range 120–491) for
the 1973–1992 and 162 months (range 120–251 months) for the
1993–2003 cohort. In similar order, the median age of patients was 26
and 27 years respectively. While the majority of patients had localized
stage cHL in both cohorts, a higher proportion of patients in the 1973–
1992 cohort received radiation therapy. Age at diagnosis, gender, and
race/ethnicity distributions were similar between the 2 eras.
3.2 | Excess mortality
The 15-year, 20-year, 25-year, and 30-year EMR for 10-year AYA cHL
survivors diagnosed during 1973–1993 was 4.88% (95% C.I. 4.36%-
5.48%); 9.46% (95% C.I. 8.72%-10.26%); 15.03% (95% C.I. 13.95-
16.18%); and 23.69% (95% C.I. 22.08%-25.58%), respectively. In the
more recent cohort, there was a substantial reduction in the 15-year
and 20-year EMR to 2.19% (95% C.I, 1.69%-2.86%, P< .0001) and
4.07% (95% C.I. 2.53%-6.52%, P< .0001), respectively (Figure 1).
3.3 | Factors associated with increased excess
mortality
When analyzing patients in the 1973–1992 cohort, we found no
difference in EMR between patients with localized (stages 1–2) and
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advanced (stages 3–4) cHL at any of the time points (Figure 2A). Male
survivors had higher EMR at 15, 20, and 25 years from diagnosis than
female survivors (Figure 2B).
In the most recent cohort (1993–2003), we found that the 15- and
20-year EMR for 10-year AYA survivors with advanced stage cHL was
3.48% (95% C.I. 2.40%-5.24%), and 6.46% (95% C.I. 3.23%-13.1%),
respectively. These results were found to be significantly higher in
comparison to survivors of localized stage cHL at 15-(1.69%, 95% C.I
1.19%-2.44%, P5 .007) and at 20-year (2.57%, 95% C.I. 1.81%-4.09%,
P5 .03) EMR treated in the same era (Figure 2D). Similarly, for patients
treated in the most recent era, there was higher EMR among male
survivors in comparison to females at 15-years post-treatment
(2.98%, 95% C.I. 2.15%-4.08% for males vs. 1.59%, 95% C.I.
1.05%-2.47% for females, P5 .02) (Figure 2E). We found no significant
difference in EMR between localized-stage patients treated with or
without radiation therapy in the 1993–2003 cohort (Figure 2F).
3.4 | Causes of death
Although it is not possible to attribute the cause of excess mortality
without information on expected COD in the general population, we
analyzed overall COD at years 10 and 15 from diagnosis as a window
into the factors possibly implicated in excess risk of death. There were
TABLE 1 Characteristics of 10-year AYA cHL survivors in the 2 consecutive eras
1973–1992
(N55870)
1993–2003
(N5 6480) P
Follow up in months, median (range) 312 (120–491) 162 (120–251) N/A
Age in years, median (range) 26 (15–39) 27 (15–39) <0.001
Male gender 3008 (51.2%) 3172 (48.9%) 0.01
Race/ethnicity <0.001
Non-hispanic black 364 (6.2%) 615 (9.5%)
Non-hispanic white 5104 (87.0%) 4783 (73.8%)
Hispanic 259 (4.4%) 761 (11.7%)
Other 115 (2.0%) 276 (4.3%)
Unknown 28 (0.5%) 45 (0.7%)
Stage (%) <0.001
1 and 2 2171 (37.0%) 4405 (68%)
3 and 4 992 (18.6%) 1750 (27%)
Unknown 2607 (44.4%) 325 (5%)
Radiation <0.001
Yes 3762 (64.1%) 3194 (49.3%)
No 1940 (33.0%) 3074 (47.4%)
Unknown 168 (2.9%) 212 (3.3%)
Histologic subtype (%) <0.001
Nodular sclerosis 4102 (69.9%) 5068 (78.2%)
Mixed-cellularity 965 (16.4%) 616 (9.5%)
Classical NOS 513 (8.7%) 606 (9.4%)
Lymphocyte-rich 228 (3.9%) 153 (2.4%)
Lymphocyte-depleted 62 (1.1%) 37 (0.6%)
FIGURE 1 Comparative 15- and 20-year excess mortality rates for
10-year survivors of adolescents and young adults with classical
Hodgkin lymphoma diagnosed between 1973–1992 and 1993–2003
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98 deaths among the 1598 patients followed for a total of 7703.2
person-years in the sub-cohort diagnosed between 1983 and 1987.
For the 1993–1997 sub-cohort, there were 67 deaths among 2196
patients followed for a total of 10 615.6 person-years.
The SMN was the leading cause of death among patients in the
1983–1987 sub-cohort, while cHL was the leading cause of the death
in the more recent sub-cohort (Table 2). There was an overall decline in
risk of death between the 2 eras, driven mostly by a reduction in
risk of death from SMN and cardiovascular causes. The reduction in
death from cHL among 10-year survivors did not reach statistical
significance.
The reduction in risk of death in years 10–15 for 10-year survivors
seems to span across both genders and it was far more pronounced
among patients with localized cHL where there was substantial reduc-
tion in risk of death from any cause (11.7 to 4.5 deaths/1000 person-
year, P< .0001), from SMN (3.2 to 1.1 deaths/1000 person-year,
P5 .012) and from cardiovascular causes (2.8 to 0.4 deaths/1000
person-year, P< .0001), but not from cHL (2.1 to 1.1 deaths/1000
person-year, P5 .16), as shown in Table 2. In addition, the reduction in
risk of death in years 10–15-year in females was driven primarily by
reduction in death from SMN (4.2 to 1.3 deaths/1000 person-year,
P5 .006), while in males the more pronounced risk reduction was in
FIGURE 2 Comparative 15- and 20-year excess mortality rates for 10-year survivors of adolescent and young adult with classical Hodgkin
lymphoma displaying A, localized stage vs. advanced stage; B, male vs. female; and C, radiation vs. no radiation treatment of patients with
localized stage for patients diagnosed between 1973–1992; and D, localized stage vs. advanced stage; E, male vs. female; and F, radiation
vs. no radiation treatment of patients with localized stage for patients diagnosed between 1993–2003
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death from cardiovascular diseases (4.2 to 1.9 deaths/1000
person-year, P5 .04). For 10-year survivors of advanced stage AYA
cHL, there was no significant reduction in the overall risk of death in the
5 subsequent years (12.2 to 10.2 deaths/1000 person-year, P5 .47).
4 | DISCUSSION
Using a large population-based data set, the present study verified that
despite significant improvements in treatment and cure rates in the
most recent years, long-term survivors of AYA cHL continue to have a
higher risk of death than matched population. Our findings are of cru-
cial importance since cHL predominantly affects AYA, individuals who
otherwise would have a long life expectancy. As the cohort ages, some
deaths are expected, as in the matched population, making it important
to use the expected mortality in the population as reference. Therefore,
using EMR allows us to determine the impact of having cHL and/or
receiving cHL therapy on the long-term risk of death.
The ideal “cure” scenario would result in long-term survivors hav-
ing the same risk of death as individuals of the same age, gender, and
race/ethnicity, resulting in EMR of zero. Unfortunately, this is not the
case despite recent advances in therapy as demonstrated in our study,
wherein patients in the 1973–1992 cohort, continued to have steady
increase in EMR beyond 20 years from diagnosis reaching 23.69% at
30 years from diagnosis (20-years follow-up of 10-year survivors)
(Figure 1). This is consistent with previous large cohorts of pediatric
and adult cHL patients diagnosed up to the mid-1990s showing
significantly increased risk of death even after 25 years post cancer
therapy.11–15
We detected a reduction in EMR in the more recent cohort. AYA
diagnosed between 1993–2003 and surviving 10 years after cHL ther-
apy had a 4% EMR after 10 years of additional follow-up (Figure 1).
That translates into 1 in 25, 10-year survivor of AYA cHL dying during
the next 10 years because they had cHL and received therapy for cHL.
The reduction in EMR across eras was driven mostly by patients
with localized disease (Figure 2A,D). This is possibly linked to de-
intensification of therapy with less toxic chemotherapy regimens,
shorter courses of chemotherapy and employment of lower doses and
smaller fields of radiation.16–19 Although the database utilized lacks
details of therapy, this possibility is further supported by our observa-
tion of a substantial reduction in risk of late mortality from SMN and
cardiovascular diseases in localized cHL survivors, 2 complications
intrinsically linked to therapy.11,20 Conversely, we did not observe a
substantial reduction in late EMR among 10-year survivors of advanced
cHL (Figure 2A,D) as survivors remained at high risk of death from cHL,
SMN, and cardiovascular disease in both eras (Table 2). This concerning
observation highlights the need to improve both the efficacy and safety
of therapies utilized in AYA with advanced cHL. The development of
novel therapies for advanced cHL needs to continue to emphasize not
only short-term efficacy but also long-term safety.
Recently, the Childhood Cancer Survivor Study (CCSS) showed sig-
nificant reductions in the rate of death (from 5.3% to 2.6%, P5 .006)
from any health-related cause 15 years from diagnosis across treatment
eras (1970–1999) among 4332 survivors of cHL diagnosed before the
age of 21.9 The CCSS investigators also demonstrated temporal reduc-
tions in chest radiotherapy and anthracycline exposure over time. Inter-
estingly, the study did not show that adjustments in therapy impacted
the relative rates of death among long-term childhood cHL survivors,
suggesting that other factors, such as better screening methods and sup-
portive care, may have played a role in reducing late mortality other than
adjustments in treatment exposure.9 Continued focus on early preventa-
tive medicine and on improving supportive care to all survivors may be
an effective way to decrease mortality among cHL survivors diagnosed
in the most recent years.
We found that SMNs are still the second most common cause of
death in long-term survivors of cHL in AYA. Reduction in risk of SMN
was seen in large cohort of pediatric cHL survivors treated over a time
span of several decades and followed for at least 15 years.2 In that
study, the authors speculated that the reduction in standardized inci-
dence ratio for SMN likely resulted from decreasing use of radiation
therapy.2 Another study, however, found no appreciable impact in the
risk of SMN in a large cohort of cHL survivors treated between 1965
and 2000. This may be likely due to the fact that current radiation ther-
apy practices, such as lower doses or smaller radiation therapy fields,
were broadly used only after 2000.21 In addition to modifications in
radiation therapy fields and doses, reduction in risk of SMN could have
resulted from minimum exposure or complete elimination of nitrogen
mustard from HL treatment regimens in the 1990s.22,23
We found reduction in deaths from SMN among survivors of local-
ized cHL but not among survivors of advanced cHL (Table 2), reinforc-
ing the hypothesis that de-intensification of therapy in localized cHL is
linked to reduction in risk of fatal SMN.
We observed a decline in the risk of death due to cardiovascular
diseases between the 2 eras (Table 2). We also found higher late EMR
among male survivors in comparison to females across eras. It is possi-
ble that this finding correlates in part with the fact that cardiovascular
diseases appear to disproportionally affect late mortality among males.
Mechanisms of cardiovascular toxicity among cHL survivors are com-
plex, multifactorial, and persist throughout life.24–27 Hypertension,
smoking, hypercholesterolemia, and diabetes are also more prevalent
among men. These factors seem to further accentuate the risk of cardi-
ovascular complications among cHL survivors that is usually driven by
radiation therapy and anthracycline exposure.20,28–30 It is possible that
reduction in deaths from cardiovascular disease reflects both improved
safety of therapy and better control of risk factors, including smoking
cessation.
Our study is met by some limitations. It is believed that the vast
majority of patients included in this cohort would have received chem-
otherapy or combined modality therapy. This information, however, is
not available in the SEER registry. Therefore, the association between
therapeutic interventions and possible outcomes should be interpreted
as hypothesis generating. Additionally, since we do not have informa-
tion on COD in the general population using the same criteria utilized
for COD assignment in SEER, it is not possible to estimate which com-
ponents of late mortality are attributable to cHL and its treatment.
However, it is reasonable to assume that the majority of the deaths,
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due to SMN, for example, were linked to prior cHL therapy in an other-
wise young patient cohort.
In conclusion, long-term survivors of AYA cHL continue to have a
higher risk of death in comparison to matched population despite
improvements in treatment and cure rates. Although advances in the
management of localized cHL have likely resulted in reduced long-term
mortality, improvements are still needed, particularly for patients with
advanced disease. Future management of cHL in AYA needs therapies
that combine improved anti-lymphoma efficacy, short and long-term
safety and are paired with a comprehensive survivorship program
aimed at reducing cardiovascular risk-factors and intervening early to
prevent long-term complications.
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